SLC3037, an NLRP3 inhibitor that blocks NEK7 [never in mitosis A (NIMA)-related kinase 7 (NEK7) critical in NLRP3 oligomerization] binding to NLRP3, shows promise as a novel agent for diseases associated with NLRP3 inflammasome activation like gout (58). This evidence concerns the gene NEK7 and gout.